Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5)

被引：0
|
作者：
E Schuler
A Giagounidis
D Haase
K Shirneshan
G Büsche
U Platzbecker
F Nolte
K Götze
R F Schlenk
A Ganser
A Letsch
F Braulke
M Lübbert
G Bug
P Schafhausen
U Bacher
N Gattermann
M Wulfert
R Haas
U Germing
机构：
[1] Oncology and Clinical Immunology,Department for Hematology
[2] University Hospital,Department of Hematology
[3] Heinrich-Heine-University,Department of Hematology
[4] Oncology and Palliative Care,Department of Hematology and Oncology
[5] Marien Hospital Duesseldorf,Department of Internal Medicine
[6] University Medicine Goettingen,Department of Internal Medicine
[7] Clinics of Hematology and Medical Oncology,Department of Hematology
[8] Hannover Medical School,Department of Hematology and Oncology
[9] Institute of Pathology,Department of Internal Medicine
[10] University Hospital Dresd,Department of Oncology
[11] en,undefined
[12] University Hospital Mannheim,undefined
[13] Technical University of Munich,undefined
[14] University Hospital Ulm,undefined
[15] Hemostasis,undefined
[16] Oncology,undefined
[17] and Stem Cell Transplantation,undefined
[18] Hannover Medical School,undefined
[19] Charité,undefined
[20] Benjamin Franklin University,undefined
[21] University Hospital Freiburg,undefined
[22] Internal Medicine,undefined
[23] University Hospital Frankfurt,undefined
[24] Hematology,undefined
[25] BMT with section Pneumology,undefined
[26] Hubertus Wald Cancer Center,undefined
[27] University Medical Center Hamburg-Eppendorf,undefined
来源：
Leukemia | 2016年 / 30卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1580 / 1582
页数：2
相关论文
共 50 条
  • [31] Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes
    Madanat, Yazan F.
    Sekeres, Mikkael A.
    Mukherjee, Sudipto
    Hirsch, Cassandra M.
    Guan, Yihong
    Nagata, Yasunobu
    Adema, Vera
    Hasipek, Metis
    Gerds, Aaron T.
    Carraway, Hetty E.
    Advani, Anjali S.
    Przychodzen, Bartlomiej P.
    Santini, Valeria
    Maciejewski, Jaroslaw P.
    Jha, Babal K.
    Nazha, Aziz
    BLOOD, 2018, 132
  • [32] Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study
    Matsuda, Akira
    Taniwaki, Masafumi
    Jinnai, Itsuro
    Harada, Hironori
    Watanabe, Mitsumasa
    Suzuki, Kenshi
    Yanagita, Soshi
    Suzuki, Takahiro
    Yoshida, Yataro
    Kimura, Akiro
    Tsudo, Mitsuru
    Tohyama, Kaoru
    Takatoku, Masaaki
    Ozawa, Keiya
    LEUKEMIA RESEARCH, 2012, 36 (05) : 575 - 580
  • [33] Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real-world setting
    Singh, Amritpal
    Al-Kali, Aref
    Foran, James M.
    Elliott, Michelle A.
    Begna, Kebede
    Badar, Talha
    Khera, Nandita
    Fleti, Farah
    Abdelmagid, Maymona
    Reichard, Kareen K.
    Ketterling, Rhett P.
    Pardanani, Animesh
    Gangat, Naseema
    Tefferi, Ayalew
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (10) : E377 - E379
  • [34] Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial
    Komrokji, Rami S.
    Al Ali, Najla H.
    Padron, Eric
    Cogle, Christopher
    Tinsley, Sara
    Sallman, David
    Lancet, Jeffrey E.
    Lis, Alan F.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (04): : 251 - 254
  • [35] The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes
    Melchert, Magda
    Kale, Vishakha
    List, Alan
    CURRENT OPINION IN HEMATOLOGY, 2007, 14 (02) : 123 - 129
  • [36] Gene expression profiling in patients with myelodysplastic syndromes, including patients with the del(5q)
    Boultwood, J.
    LEUKEMIA RESEARCH, 2009, 33 : S3 - S4
  • [37] Efficacy to lenalidomide treatment and complete cytogenetic remission in a case of myelodysplastic syndrome with del(5q) and del(9q)
    Xiong, Bei
    Liu, XinYue
    Zou, Ping
    Fan, LiHua
    Chen, WanXin
    Li, WeiMing
    Liu, Lin
    LEUKEMIA RESEARCH, 2010, 34 (07) : E169 - E172
  • [38] Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment
    Acha, Pamela
    Mallo, Mar
    Sole, Francesc
    CANCERS, 2022, 14 (22)
  • [39] Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation
    Nomdedeu, Meritxell
    Maffioli, Margherita
    Calvo, Xavier
    Martinez-Trillos, Alejandra
    Baumann, Tycho
    Diaz-Beya, Marina
    Aguilar, Josep-Lluis
    Rozman, Maria
    Costa, Dolors
    Esteve, Jordi
    Cervantes, Francisco
    Colomer, Dolors
    Nomdedeu, Benet
    LEUKEMIA RESEARCH, 2011, 35 (09) : 1276 - 1278
  • [40] “Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)”
    Bengt Rasmussen
    Gudrun Göhring
    Elsa Bernard
    Lars Nilsson
    Magnus Tobiasson
    Martin Jädersten
    Hege Garelius
    Ingunn Dybedal
    Kirsten Grønbaek
    Elisabeth Ejerblad
    Fryderyk Lorenz
    Max Flogegård
    Claus Werenberg Marcher
    Annette Öster Fernström
    Lucia Cavelier
    Elli Papaemmanuil
    Freja Ebeling
    Astrid Olsnes Kittang
    Jan Maxwell Nørgaard
    Leonie Saft
    Lars Möllgård
    Eva Hellström-Lindberg
    Leukemia, 2022, 36 : 1436 - 1439
12345